Neurology News

Researchers found that topical CBD products purchased online and in retail stores were often inaccurately labeled, and many contained THC, highlighting the need for improved regulatory oversight, according to a report in JAMA Network Open.

The FDA has approved Neuronetics’ NeuroStar Advanced Therapy for Mental Health, a transcranial magnetic stimulation system for treatment of anxiety symptoms in adults with major depressive disorder, the company announced in a press release.

Year after year, Healio and Healio LIVE teams have garnered increasing numbers of APEX awards for publication excellence, this year bringing in 10 total, including three grand awards.

Maintaining optimal CV health by following the American Heart Association’s Life’s Simple 7 protected people from stroke, even among those at high genetic risk, data from a long-term analysis show.

The U.S. Supreme Court’s recent decision to overturn Roe v. Wade will compromise standard neurological care for approximately 40 million women in as many as 28 states, educators wrote in JAMA Neurology.

The COVID-19 pandemic negatively impacted caregivers and non-caregivers alike, with evidence of increased alcohol consumption and depressive symptoms along with significant sleep disturbances, according to a study published in Alcohol.

The FDA has granted tentative approval to Lumryz, a once-at-bedtime oral treatment for excessive daytime sleepiness or cataplexy in adults with narcolepsy, Avadel Pharmaceuticals announced in a press release.

Avant Institute received a grant from Davos Alzheimer’s Collaborative to perform cognitive screening at pharmacies in rural and underserved communities nationwide, according to a press release.

Adherence to a Mediterranean diet was associated with better cognitive performance and decreased learning and memory decline after 7 years among middle-aged and older Hispanic or Latino adults, per a study published in JAMA Network Open.

The FDA has granted approval to Azurity Pharmaceuticals Inc. for its oral adjunctive therapy to treat partial seizures in adolescents and adults aged 16 years and older with epilepsy.